Provided herein are methods of treating a viral infection in a subject in need thereof, comprising administering to the subject a compound of Formula (I), or a pharmaceutical composition comprising Formula (I). Further provided herein are methods for inhibiting the replication of a virus (e.g., a togaviridae family virus (e.g., an alphavirus (e.g., Chikungunya virus, Eastern equine encephalitis, Mayaro virus, Venezuelan equine encephalitis virus, Western equine encephalitis)), a filoviradae family virus (e.g., a Marburg virus (e.g., Marburg virus, Ravn virus)), human respiratory syncytial virus (i.e., human orthopneumo virus), a flavivirus (e.g., dengue virus, Usutu virus, Japanese encephalitis virus, Powassan virus, yellow fever), a paramyxoviridae family virus (e.g., an orthoparamyxovirinae virus (e.g., a henipavims (e.g., Nipah virus), a morbillivims (e.g., measles morbillivirus))) in a subject in need thereof. Also provided herein are methods for treating and/or preventing a disorder due to a microbial toxin (e.g., due to P. aeruginosa exotoxin A, Clostridium septicum alpha-toxin, diphtheria toxin(s), shiga toxin(s)) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), or a pharmaceutical composition comprising a compound of Formula (I) as described herein. Also provided are pharmaceutical compositions and kits including a compound of Formula (I) for use in the treatment and/or prevention of a viral infection in a subject in need thereof.

##STR00001##

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.

Methods and combination therapies for treating, preventing, and/or delaying the onset and/or development of cancer using a tubulin polymerization inhibitor such as a compound of formula I, or a pharmaceutically acceptable salt thereof, and a poly (ADP-ribose) polymerase (PARP) inhibitor, or a pharmaceutically acceptable salt thereof, are provided.

Compounds of Formula I, its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof and pharmaceutical compositions containing them as the active ingredient which can be used as medicaments are provided. The aforementioned substances can also be used in the manufacture of medicaments for treatment, prevention, or suppression of diseases, and conditions mediated by microbes. Methods for the synthesis and characterization of the aforementioned substances are also provided. ##STR00001##

The invention relates to differentiation methods for progenitor cells, e.g. mammalian epithelial stem cells, differentiation media for use in said methods, organoids and cells obtainable by said methods and uses, including therapeutic uses, thereof.

Disclosed are immunotherapeutic compositions and the concurrent use of combinations of such compositions for the improved induction of therapeutic immune responses and/or for the prevention, amelioration and/or treatment of disease, including, but not limited to, cancer and infectious disease.

A series of S-triazolyl α-mercaptoacetanilides having general structure (1) are provided, where Q is CO.sub.2H, CONR.sub.2, SO.sub.3H, or SO.sub.2NR.sub.2. The compounds inhibit several variants of the reverse transcriptase of HIV, and are useful in the treatment of HIV infections.

##STR00001##

Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure:

##STR00001##

Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.

This invention relates to compositions including Clostridium difficile toxins and/or toxoids and corresponding methods. The compositions of the invention include one or more excipients that increase stability and/or decrease aggregation of the toxins.

This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula:

##STR00001##

wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.